Sophie Park

6.6k total citations
93 papers, 2.6k citations indexed

About

Sophie Park is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Sophie Park has authored 93 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Hematology, 36 papers in Genetics and 29 papers in Molecular Biology. Recurrent topics in Sophie Park's work include Acute Myeloid Leukemia Research (52 papers), Multiple Myeloma Research and Treatments (15 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Sophie Park is often cited by papers focused on Acute Myeloid Leukemia Research (52 papers), Multiple Myeloma Research and Treatments (15 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Sophie Park collaborates with scholars based in France, United States and Germany. Sophie Park's co-authors include Didier Bouscary, François Dreyfus, Valérie Bardet, Nicolas Chapuis, Patrick Mayeux, Jérôme Tamburini, Lise Willems, Norbert Ifrah, Alexa S. Green and Catherine Lacombe and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Sophie Park

89 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sophie Park France 26 1.4k 1.3k 721 385 322 93 2.6k
Véronique Mansat‐De Mas France 25 1.3k 0.9× 1.4k 1.1× 546 0.8× 428 1.1× 141 0.4× 57 2.5k
Fumihiko Hayakawa Japan 26 1.4k 1.0× 1.1k 0.9× 430 0.6× 624 1.6× 257 0.8× 85 2.4k
Keita Kirito Japan 29 1.2k 0.8× 1.1k 0.8× 585 0.8× 433 1.1× 206 0.6× 128 2.3k
Pascale Cornillet‐Lefèbvre France 23 793 0.6× 931 0.7× 328 0.5× 313 0.8× 221 0.7× 49 2.0k
José Cervera Spain 29 1.4k 1.0× 1.5k 1.2× 519 0.7× 341 0.9× 246 0.8× 129 2.6k
Tetsuzo Tauchi Japan 30 1.6k 1.1× 1.5k 1.2× 911 1.3× 621 1.6× 199 0.6× 146 3.1k
Utz Krug Germany 25 1.1k 0.8× 980 0.8× 282 0.4× 432 1.1× 177 0.5× 82 2.0k
Kensuke Kojima Japan 29 1.8k 1.3× 959 0.8× 444 0.6× 1.1k 2.8× 320 1.0× 135 2.9k
Hélène Lapillonne France 22 1.5k 1.0× 905 0.7× 495 0.7× 285 0.7× 145 0.5× 57 2.7k
Hirotaka Matsui Japan 28 1.4k 1.0× 780 0.6× 279 0.4× 368 1.0× 145 0.5× 116 2.3k

Countries citing papers authored by Sophie Park

Since Specialization
Citations

This map shows the geographic impact of Sophie Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sophie Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sophie Park more than expected).

Fields of papers citing papers by Sophie Park

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sophie Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sophie Park. The network helps show where Sophie Park may publish in the future.

Co-authorship network of co-authors of Sophie Park

This figure shows the co-authorship network connecting the top 25 collaborators of Sophie Park. A scholar is included among the top collaborators of Sophie Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sophie Park. Sophie Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kwong, Brandon, Joseph Banuelos, Petro Starokadomskyy, et al.. (2024). POS0462 PRECLINICAL DEVELOPMENT OF KYV-201, AN INVESTIGATIONAL ALLOGENEIC ANTI-CD19 CAR T CELL FOR THE TREATMENT OF AUTOIMMUNE DISEASE. Annals of the Rheumatic Diseases. 83. 1129–1130. 2 indexed citations
3.
Cahn, Jean‐Yves, Anne Thiebaut‐Bertrand, Claude‐Eric Bulabois, et al.. (2024). Rapid response system for critically ill patients with haematological malignancies: A pre‐ and post‐intervention study. European Journal Of Haematology. 113(3). 330–339.
4.
Laurin, David, et al.. (2023). Extracellular Vesicles and MicroRNA in Myelodysplastic Syndromes. Cells. 12(4). 658–658. 5 indexed citations
5.
Park, Sophie, Jean‐François Hamel, Andréa Toma, et al.. (2020). Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. Leukemia Research. 99. 106472–106472. 2 indexed citations
6.
Pernet‐Gallay, Karin, Julie Brault, David Laurin, et al.. (2019). Tumor microenvironment and clonal monocytes from chronic myelomonocytic leukemia induce a procoagulant climate. Blood Advances. 3(12). 1868–1880. 10 indexed citations
7.
Park, Sophie, Peter L. Greenberg, Aylin Yücel, et al.. (2018). Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review. British Journal of Haematology. 184(2). 134–160. 36 indexed citations
8.
Grignano, Éric, A. Mékinian, Thorsten Braun, et al.. (2016). Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review. Leukemia Research. 47. 136–141. 36 indexed citations
9.
Lefebvre, Christine, Josiane Arnaud, Catherine Garrel, et al.. (2016). Mechanisms of Improvement of Erythropoiesis with Low Dose Deferasirox in Low Risk Myelodysplastic Syndromes. Blood. 128(22). 3152–3152. 2 indexed citations
10.
Park, Sophie, Pierre Fenaux, Peter L. Greenberg, et al.. (2016). Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta‐analysis. British Journal of Haematology. 174(5). 730–747. 27 indexed citations
11.
Natarajan‐Amé, Shanti, Sophie Park, Lionel Adès, et al.. (2012). Bortezomib combined with low‐dose cytarabine in Intermediate‐2 and high risk myelodysplastic syndromes. A phase I / II Study by the GFM. British Journal of Haematology. 158(2). 232–237. 12 indexed citations
12.
Payet, Judith, Niloufar Kavian, Olivia Chandesris, et al.. (2012). Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. Leukemia & lymphoma. 54(4). 767–777. 30 indexed citations
13.
14.
Chapuis, Nicolas, Jérôme Tamburini, Alexa S. Green, et al.. (2010). Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia. Clinical Cancer Research. 16(22). 5424–5435. 128 indexed citations
15.
Chapuis, Nicolas, Sophie Park, Laurent Léotoing, et al.. (2010). IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia. Blood. 116(20). 4240–4250. 68 indexed citations
16.
Park, Sophie, Nicolas Chapuis, Jérôme Tamburini, et al.. (2009). Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 95(5). 819–828. 236 indexed citations
17.
Chapuis, Nicolas, Jérôme Tamburini, Pascale Cornillet‐Lefèbvre, et al.. (2009). Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica. 95(3). 415–423. 113 indexed citations
18.
Tamburini, Jérôme, Alexa S. Green, Valérie Bardet, et al.. (2009). Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood. 114(8). 1618–1627. 144 indexed citations
19.
Kelaïdi, Charikleia, Sophie Park, Sabine Bréchignac, et al.. (2008). Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leukemia Research. 32(7). 1049–1053. 59 indexed citations
20.
Tamburini, Jérôme, Caroline Elie, Valérie Bardet, et al.. (2007). Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood. 110(3). 1025–1028. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Véronique Mansat‐De Mas Breakdown of academic impact, for papers by Fumihiko Hayakawa Breakdown of academic impact, for papers by Keita Kirito Breakdown of academic impact, for papers by Pascale Cornillet‐Lefèbvre Breakdown of academic impact, for papers by José Cervera Breakdown of academic impact, for papers by Tetsuzo Tauchi Breakdown of academic impact, for papers by Utz Krug Breakdown of academic impact, for papers by Kensuke Kojima Breakdown of academic impact, for papers by Hélène Lapillonne Breakdown of academic impact, for papers by Hirotaka Matsui
Rankless by CCL
2026